Recent studies have shown that CD206-expressing TAMs are also capable of cross-presenting tumor-associated antigens to activate T cells (7), suggesting that CD206-directed therapies may inadvertently deplete beneficial TAMs. This evidence concerns the gene MRC1 and neoplasm.